Reply to the letter of inquiry regarding abnormal fluctuations in stock trading of Guangzhou Anbiping Pharmaceutical Technology Co., Ltd.
Reply to the “Letter of Inquiry on Abnormal Fluctuations in Stock Trading of Guangzhou Anbiping Pharmaceutical Technology Co., Ltd.”
Announcement on the resignation of core technical personnel
Notice on the Change of Sponsor Representative for Continued Supervision
Notice on the Change of Sponsor Representative for Continued Supervision
Announcement on voluntary disclosure of the qualifications obtained by the company and its subsidiaries from July to September 2024
Announcement on the use of own funds for cash management
Announcement on voluntary disclosure of the qualification status of the company and its subsidiaries from April to June 2024.
Legal Opinion of Guangdong Cinda Law Firm on the 2023 Annual General Meeting of Shareholders of Guangzhou Anbiping Pharmaceutical Technology Co., Ltd.
Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders
Notice on Voluntary Disclosure of Obtaining a Medical Device Registration Certificate
2023 Annual General Meeting of Shareholders Meeting Materials
Announcement on the annulled portion of 2022 restricted shares granted that have not yet been vested
2024 “Improve Quality, Increase Efficiency, and Focus on Return” Special Action Plan
Notice on changing the scope of business, amending the “Articles of Association”, and registration of industrial and commercial changes
Announcement on the termination of the issuance of convertible corporate bonds to unspecified targets
Notice on convening the 2023 Annual General Meeting of Shareholders
Notice on requesting the shareholders' meeting to authorize the board of directors to issue shares to specific targets through simple procedures
Announcement on the addition of certified core technical personnel
2023 Internal Control Evaluation Report